US health authorities on Friday (January 6th) authorized a new Alzheimer's drug aimed at reducing cognitive decline in patients suffering from this neurodegenerative disease, a much-anticipated treatment after the failed launch of a previous drug with a similar mechanism a year ago and half.
The new treatment, which will be marketed under the name Leqembi, is now recommended by the American Medicines Agency (FDA) for patients who have not yet reached a very advanced stage of the disease.